Circular RNA Vaccines: Promise for Cancer Treatment and the Evidence Still Needed to Show Clinical Superiority
Background: Does RNA that lasts longer make a better vaccine?
It remains unclear whether the high molecular stability of circular RNA (circRNA) produces better vaccine effects in people. An editorial published in Nature Biotechnology on May 11, 2026, described the promise seen in preclinical studies while cautioning that it is too early to treat those findings as evidence that circRNA vaccines are superior to existing messenger RNA (mRNA) vaccines. The piece was a commentary reviewing several studies and development challenges, not a report of new experimental results.
CircRNA is a single-stranded RNA whose two ends are covalently joined. Its ring structure, with no free ends, makes it resistant to enzymatic degradation, and it can be designed to produce proteins for a sustained period in mammalian cells. These properties have drawn interest in circRNA as a platform for supplying vaccine antigens over time. However, how long RNA persists, how long an antigen is produced, and how long immune protection lasts are distinct questions. The editorial noted that existing mRNA vaccines also generate strong, durable immunity in many settings, and that it remains unresolved whether simply increasing antigen expression improves vaccination outcomes.
Key findings: Preclinical promise observed in cancer vaccines
The editorial focused in particular on cancer vaccines. Because overcoming the immunosuppressive tumor environment requires eliciting T-cell responses that attack cancer cells, sustained antigen presentation could potentially help. This possibility should be distinguished from therapeutic benefit demonstrated in people.
In a 2025 study described by the editorial, a vaccine containing a small circRNA had a longer shelf life than comparator vaccines containing linear mRNA, larger circRNA, or modified mRNA designed for greater stability, and elicited stronger immune-cell responses in mice. The editorial did not provide specific storage conditions or effect sizes. These findings alone do not provide enough evidence to conclude that refrigeration during distribution is unnecessary.
Neoantigen vaccines targeting mutations in individual tumors are another potential application. According to the editorial, in a mouse model of colon adenocarcinoma, combining a circRNA neoantigen vaccine with an anti-PD-1 immune checkpoint inhibitor increased infiltration of CD8-positive T cells into tumors and suppressed tumor growth. However, the neoantigen vaccine studies cited by the editorial had small sample sizes, and the hepatocellular carcinoma and melanoma studies did not directly compare circRNA vaccines with mRNA vaccines. This is why results from particular animal experiments cannot readily be generalized to superiority of the circRNA platform as a whole.
Implications and outlook: Infectious disease prevention and clinical translation require separate validation
Potential has also been observed for infectious disease vaccines. The editorial described studies in mice and nonhuman primates in which circRNA vaccines elicited strong antibody and T-cell responses against SARS-CoV-2 and its variants. However, it has not been established whether prolonged antigen expression leads to longer-lasting protection than existing mRNA vaccines or reduces the need for booster doses. The benefit expected from sustained antigen stimulation in cancer cannot be assumed to apply equally to infectious disease prevention.
Barriers to clinical translation also remain. At the time of publication, the editorial stated that circRNA vaccines had not yet reached evaluation in clinical trials, and identified improvements in delivery technology and proof of scalability for manufacturing as outstanding challenges. The safety implications of long-term RNA persistence are also uncertain. This was the editorial’s assessment in May 2026 and does not describe development status after that date. Until safety and efficacy are established in people, protection for months after a single dose and lower supply costs are difficult to present as established advantages.
Source: Nature Biotechnology editorial, “Circling back to RNA vaccines”
Nature Biotechnology, Published online: 11 May 2026; doi:10.1038/s41587-026-03155-8While circRNA is often framed as a more stable, longer-lasting alternative to linear mRNA, its real-world advantages remain largely theoretical, and it is unclear whether greater molecular stability will translate into meaningful clinical gains.
For cancer vaccine development teams choosing circRNA, a central question is whether sustained antigen supply adds a real therapeutic benefit when combined with immune checkpoint inhibitors. For example, if developing a neoantigen vaccine containing mutations from an individual patient’s tumor, teams should separately assess the duration of antigen expression, intratumoral T-cell responses, and tumor suppression. Responses observed in mice alone are difficult to use to predict therapeutic benefit in people. For infectious disease vaccines, too, the priority is to establish added benefits in protection duration and safety compared with existing vaccines, rather than relying on prolonged expression itself. Potential manufacturing and supply advantages can be assessed only after storage conditions, delivery performance, and scalability have been validated for the actual formulation.